Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

IMPORTANCE: Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease. OBJECTIVE: To evaluate the effect of...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JAMA
Asıl Yazarlar: Rosenstock, Julio, Perkovic, Vlado, Johansen, Odd Erik, Cooper, Mark E., Kahn, Steven E., Marx, Nikolaus, Alexander, John H., Pencina, Michael, Toto, Robert D., Wanner, Christoph, Zinman, Bernard, Woerle, Hans Juergen, Baanstra, David, Pfarr, Egon, Schnaidt, Sven, Meinicke, Thomas, George, Jyothis T., von Eynatten, Maximilian, McGuire, Darren K.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Medical Association 2018
Konular:
Original Investigation
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6583576/
https://ncbi.nlm.nih.gov/pubmed/30418475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2018.18269
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller